Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials (Q34818636)

4 August 2017

11 references

13 March 2019

17 June 2019

30 June 2019

27 September 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

27 November 2019

13 December 2019

26 October 2020

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials (English)

1 reference

4 August 2017

11 references

13 March 2019

17 June 2019

30 June 2019

27 September 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

27 November 2019

13 December 2019

26 October 2020

1 reference

27 September 2019

1 reference

1 October 2019

1 reference

7 November 2019

macromolecular substance

1 reference

16 November 2019

1 reference

20 November 2019

1 reference

27 November 2019

1 reference

13 December 2019

immunosuppressive drug

1 reference

26 October 2020

Ronald van Vollenhoven

7

object named as

R van Vollenhoven

1 reference

4 August 2017

V P Bykerk

1

1 reference

4 August 2017

J Cush

2

1 reference

4 August 2017

K Winthrop

3

1 reference

4 August 2017

L Calabrese

4

1 reference

4 August 2017

O Lortholary

5

1 reference

4 August 2017

M de Longueville

6

1 reference

4 August 2017

X Mariette

8

1 reference

4 August 2017

language of work or name

English

0 references

publication date

3 October 2013

1 reference

Annals of the Rheumatic Diseases

4 August 2017

1 January 2015

11 references

13 March 2019

17 June 2019

30 June 2019

27 September 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

27 November 2019

13 December 2019

26 October 2020

12 references

4 August 2017

13 March 2019

17 June 2019

30 June 2019

27 September 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

27 November 2019

13 December 2019

26 October 2020

74

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

96-103

1 reference

Creative Commons Attribution-NonCommercial

4 August 2017

copyright license

11 references

13 March 2019

17 June 2019

30 June 2019

27 September 2019

1 October 2019

7 November 2019

16 November 2019

20 November 2019

27 November 2019

13 December 2019

26 October 2020

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Assessing the safety of biologic agents in patients with rheumatoid arthritis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Certolizumab pegol for the treatment of Crohn's disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Safety of biologic therapy in rheumatoid arthritis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Integrated safety in tocilizumab clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Adverse effects of biologics: a network meta-analysis and Cochrane overview

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

The incidence of gastrointestinal perforations among rheumatoid arthritis patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4283674

Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.

8 July 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203660

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203660

Infections in patients with rheumatoid arthritis treated with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203660

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203660

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-203660

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis

21 January 2018

1 reference

12 December 2020

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

1 reference

12 December 2020

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

12 December 2020

Demyelinating events in rheumatoid arthritis after drug exposures

1 reference

12 December 2020

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

1 reference

12 December 2020

Erwünscht, ungewohnt und kommunikationsbedürftig – Die evidenzbasierte Entscheidungshilfe des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

1 reference

12 December 2020

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

1 reference

12 December 2020

10.1136/ANNRHEUMDIS-2013-203660

Identifiers

DOI

1 reference

4 August 2017

1 reference

4 August 2017

1 reference